Skip to main content
Fig. 3 | BMC Medicine

Fig. 3

From: A randomized, open-label, multi-center, active-controlled phase II study comparing abiraterone acetate tablets (II), an improved formulation, versus originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer

Fig. 3

PSA-50 response rate on Days 28, 56, and 84. PSA-50 response rate was defined as the percentage of patients with ≥ 50% reduction in total serum PSA level from baseline. AAT(II), abiraterone acetate tablets (II); OAA, originator abiraterone acetate; PSA, prostate-specific antigen

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us